Article
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2020
Pilla Reddy Venkatesh, Anjum Rana, Grondine Michael, Smith Aaron, Bhavsar Deepa, Barry Evan, Guichard Sylvie M, Shao Wenlin, Kettle Jason G, Brown Crystal, Banks Erica, Jones Rhys D O
Abstract excerpt
PURPOSE: The emergence of secondary mutations is a cause of resistance to current KIT inhibitors used in the treatment of patients with gastrointestinal stromal tumors (GIST). AZD3229 is a selective inhibitor of wild-type KIT and a wide spectrum of primary and secondary mutations seen in patients with GIST. The objective of this analysis is to establish the pharmacokinetic-pharmacodynamic (PKPD) relationship of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.